Sempulse® Positions FDA-Cleared Halo™ Platform as an Innovation Accelerator at PwC’s 2025 Emerging Tech Exchange
Dana Point, CA – March 14, 2025 – Sempulse, a leader in innovative wearable medical technology, proudly participated in PwC’s Emerging Tech Exchange held from February 26 to 28, 2025, in Dana Point, CA. As the sole startup presenting a production-ready solution, Sempulse demonstrated its FDA-cleared Halo™ Vital Signs Monitoring System, underscoring its commitment to driving industry innovation and advancing healthcare technology.
The Emerging Tech Exchange, hosted by PwC, is a prestigious gathering that brings together senior executives, academics, scientists, and entrepreneurs to exchange knowledge and collaborate on solving critical business and societal challenges. Established over 25 years ago, the Exchange has earned a reputation for fostering meaningful connections and delivering cutting-edge content.
This year’s event, held against the scenic backdrop of Dana Point, brought together visionaries and experts from across the tech landscape to foster collaboration and accelerate transformative ideas. PwC, renowned for its expertise in professional services and digital transformation, continues to spearhead initiatives that highlight emerging technologies and disruptive solutions. Attendance is by invitation only, ensuring a focused environment for innovation and collaboration.
Among a diverse lineup of presenters, Sempulse stood apart as the sole startup with a production-ready solution, offering a tangible demonstration of its advanced platform’s capabilities. Kurt Stump, Founder and CEO of Sempulse, delivered an insightful TED-style talk titled “Accelerating Innovation with the Sempulse Halo Platform.” His talk highlighted the platform’s capabilities, including its non-invasive design and real-time monitoring features, which are poised to revolutionize patient care across various settings, while focusing on the art of using today’s technologies to solve tomorrow’s problems.
“Our participation at the PwC Emerging Tech Exchange underscored Sempulse’s dedication to delivering robust, scalable solutions for healthcare that are ready for immediate implementation,” said Kurt Stump. “It is an exciting time for our company and for the industry as a whole, as we continue to push the boundaries and scale of what is possible with our technology.”
For more information about Sempulse, the Halo™ Vital Signs Monitoring System, and its other innovative solutions, please visit sempulse.com.
About Sempulse:
Founded in 2016, Sempulse is a medical device manufacturer with offices in San Marcos, TX. They are a leading innovator in wearable medical technology. They have developed and patented the first true FDA-cleared medical wearable: a novel, non-invasive vital signs sensor that adheres to the neck and the back of the ear and acquires multiple patients’ vital signs while at rest or on the go, including SpO2, pulse rate, respiratory rate, core body temperature, and skin temperature, plus geolocation and a wealth of environmental information. Sempulse empowers first responders, clinicians, and industry with real-time physiological data inside or out of the hospital, improving patient outcomes when every second counts.
Sempulse’s Halo Platform recently saved its first life. The Sempulse Halo, including the Halo sensor device, the LiveCharts app, and the Command Cloud application, provided real-time physiological data that led to life-saving action in Gwinnett County, GA.
About PwC and the Emerging Tech Exchange:
PwC, one of the world’s leading professional services firms, is committed to helping organizations navigate complex technological landscapes and drive strategic growth. The Emerging Tech Exchange is one of PwC’s signature events that has a long history of spotlighting breakthrough innovations and facilitating meaningful dialogue between established industry leaders and emerging tech startups. The event has consistently been recognized for its role in identifying and nurturing next-generation solutions that shape the future of business.
###
If you would like more information about this topic or to speak with the CEO, please email pr@sempulse.com.